Doç. Dr. PELİN AYTAN
- Yöksis ID 132768
- Researcher ID
- ORCID ID 0000-0002-4213-1565
- Scopus ID
- Scholar ID
- E-posta drpelinaytan @mersin.edu.tr
- Dahili Telefon
Birim
TIP FAKÜLTESİ
DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
İÇ HASTALIKLARI ANABİLİM DALI
DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
İÇ HASTALIKLARI ANABİLİM DALI
ÜAK Temel Alan Bilgisi
Sağlık Bilimleri Temel Alanı
Hematoloji (İç Hastalıkları)
Hematoloji (İç Hastalıkları)
Son 5 Makale
The Comparative Prognostic Value of the Interim PET Deauville Score and ΔSUVmax in Classical Hodgkin Lymphoma: A Real-World Study of Imaging and Inflammatory Markers
Journal of Clinical Medicine, vol. 15, no. 19, pp. 7353–14 Link 2026
Effectiveness and Safety of Therapeutic Plasma Exchange in Intoxication Cases: A Single-Center Retrospective Study
Çukurova Anestezi ve Cerrahi Bilimler Dergisi, vol. 9, no. 3, pp. 781–789 Link 2026
Safety profile and predictors of procedural complications in automated erythrocytapheresis for sickle cell disease: a single-center retrospective cohort study
Journal of Current Hematology & Oncology Research, vol. 4, no. 3, pp. 110–115 Link 2026
Disease Subtype and Procedural Determinants of Leukapheresis Efficacy: A Retrospective Single-Center Study
JOURNAL OF CLINICAL MEDICINE, vol. 15, no. 16, pp. 6235–12 Link 2026
Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology
JOURNAL OF CLINICAL MEDICINE, vol. 15, no. 16, pp. 6350– Link 2026
Journal of Clinical Medicine, vol. 15, no. 19, pp. 7353–14 Link 2026
Effectiveness and Safety of Therapeutic Plasma Exchange in Intoxication Cases: A Single-Center Retrospective Study
Çukurova Anestezi ve Cerrahi Bilimler Dergisi, vol. 9, no. 3, pp. 781–789 Link 2026
Safety profile and predictors of procedural complications in automated erythrocytapheresis for sickle cell disease: a single-center retrospective cohort study
Journal of Current Hematology & Oncology Research, vol. 4, no. 3, pp. 110–115 Link 2026
Disease Subtype and Procedural Determinants of Leukapheresis Efficacy: A Retrospective Single-Center Study
JOURNAL OF CLINICAL MEDICINE, vol. 15, no. 16, pp. 6235–12 Link 2026
Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology
JOURNAL OF CLINICAL MEDICINE, vol. 15, no. 16, pp. 6350– Link 2026
Son 5 Bildiri
HODGKİN LENFOMA HASTALARINDA İLK SIRA TEDAVİDE BV+AVD VE ABVD REJİMLERİNİN KARŞILAŞTIRILMASI: THD
LENFOMA AKADEMİSİ ÇALIŞMA GRUBU
51. Ulusal Hematoloji Kongresi (28.10.2025 - ) Link 2025
PERİFERİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILACAK HASTALARDA YÜZEY BELİRTEÇLERİNİN ARAŞTIRILMASI
TÜRK KLİNİK BİYOKİMYA DERNEĞİ XXV. Ulusal Klinik Biyokimya Kongresi (08.05.2025 - 11.05.2025) Link 2025
Investigation of the possible role of Tool-like receptor 4 (rs4986790) polmyhorpism in patients diagnosed with immune thrombocytopenic purpura (ITP)
The 49th FEBS Congress (05.07.2025 - 09.07.2025) Link 2025
Practical management of chronic myelomonocytic leukemia
9th AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM (16.09.2022 - ) Link 2022
A new marker for the diagnosis of pelvic inflammatory disease: immature granulocyte
University of Health Sciences, International Gynaecology and Neonatal Days (18.03.2021 - 21.03.2021) Link 2021
51. Ulusal Hematoloji Kongresi (28.10.2025 - ) Link 2025
PERİFERİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILACAK HASTALARDA YÜZEY BELİRTEÇLERİNİN ARAŞTIRILMASI
TÜRK KLİNİK BİYOKİMYA DERNEĞİ XXV. Ulusal Klinik Biyokimya Kongresi (08.05.2025 - 11.05.2025) Link 2025
Investigation of the possible role of Tool-like receptor 4 (rs4986790) polmyhorpism in patients diagnosed with immune thrombocytopenic purpura (ITP)
The 49th FEBS Congress (05.07.2025 - 09.07.2025) Link 2025
Practical management of chronic myelomonocytic leukemia
9th AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM (16.09.2022 - ) Link 2022
A new marker for the diagnosis of pelvic inflammatory disease: immature granulocyte
University of Health Sciences, International Gynaecology and Neonatal Days (18.03.2021 - 21.03.2021) Link 2021